Recent Updates
Recently added Catalysts
LUCD Positive Sentiment

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023

Key Takeaway: Lucid Diagnostics announced a business update conference call scheduled for November 14, 2023, at 8:30 AM EST. During this call, CEO Lishan Aklog will discuss the company's operations and growth strategy. CFO Dennis McGrath will present the financial results for the third quarter of 2023. The event reflects the company's commitment to transparency and stakeholder communication in the cancer prevention space.
Price reaction · baseline $1.29 (2023-10-30 close) · hit after-hours · 1 other LUCD headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Lucid Diagnostics is hosting a business update conference call, indicating active engagement with stakeholders.
  • The company is focusing on cancer prevention, a highly relevant and impactful area in healthcare.
  • Lucid's technology aims to detect esophageal precancer early, potentially saving lives.

Full Press Release Details

Conference Call and Webcast at 8:30AM Eastern Time
NEW YORK, Oct. 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, November 14, 2023, at 8:30 AM EST. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third-quarter 2023 financial results.
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-833-816-1418 and international listeners should dial 1-412-317-0511. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test is performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device. EsoGuard and EsoCheck are the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

Frequently Asked Questions

When is the Lucid Diagnostics conference call scheduled?

The conference call is set for November 14, 2023, at 8:30 AM EST.

Who will present during the Lucid conference call?

Lishan Aklog, M.D., and Dennis McGrath will present updates and financial results.

How can I access the Lucid Diagnostics webcast?

The webcast is available on Lucid's investor relations website at luciddx.com.

What is Lucid Diagnostics focused on?

Lucid Diagnostics specializes in cancer prevention, particularly for GERD patients.

How long will the conference call replay be available?

The conference call replay will be accessible for 30 days on their website.

Last updated: Oct 31, 2023